Quantum News
Sign InSign Up
Back to News
investment

Collegium Pharmaceutical, Inc. 2025 Q4 - Results - Earnings Call Presentation

Seeking Alpha
Loading...
1 min read
0 likes
⚡ Quantum Brief
Collegium Pharmaceutical reported Q4 2025 earnings, missing analyst expectations with EPS of $2.04, falling $0.10 short of projections. Revenue reached $205.45 million, a 12.92% year-over-year increase but $913,400 below estimates, signaling slower-than-expected growth. The earnings call slide deck was released in late February 2026, accompanying the company’s financial disclosures and operational updates. The results reflect ongoing challenges in meeting market forecasts despite double-digit revenue growth, raising investor concerns about future performance. The transcript was published by Seeking Alpha’s dedicated team, which covers thousands of quarterly earnings calls for public companies.
AI Audio Summary
0:00 / 0:00
Click to play
463705f9-4a81-4f55-a5b6-c84dd4da6634.jpeg
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts158.73K FollowersFollow5ShareSaveCommentsQ4: 2026-02-26 Earnings SummaryInsightsTranscript InsightsTranscriptPR10-KEPS of $2.04 misses by $0.10 | Revenue of $205.45M (12.92% Y/Y) misses by $913.40KThe following slide deck was published by Collegium Pharmaceutical, Inc. in conjunction with their 2025 Q4 earnings call. This article was written bySA Transcripts158.73K FollowersFollowSeeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Read Original

Tags

drug-discovery

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.